EAEPC blames the new export restrictions for medicines shortages in Romania

11 April 2017

New measures introduced by Romania’s Ministry of Health Order 269/2017 are to blame for medicines shortages, as these target all the medicines available in Romania with no time limit, says the European Association of Euro-Pharmaceutical Companies (EAEPC).

While this type of restriction measures is in total contradiction with European Union law (in particular art.35 and 36 TFUE) and jurisprudence, one should note that they are also in total contradiction with the reality and declared objective to fight against shortages.

Indeed, according to the list released by the same Ministry of Health, there are about 20 medicinal products in short supply, of which 50% are even not subject to intra-European Trade. But the new export restriction measures concern thousands of products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK